Letter Agreement Signed

Today, we signed a letter agreement covering our proprietary molecular assets—an important milestone as we advance the development of our therapeutic platforms.

We are currently developing two distinct drug discovery platforms. The first centers on azocinoindoles, a novel class of compounds that demonstrate non-hallucinogenic full agonism at the 5-HT2A receptor. These compounds have the potential to become the first truly non-hallucinogenic psychedelics and are being developed for the treatment of anxiety and depression. Unlike current standards of care, such as SSRIs and SNRIs, our approach offers the possibility of durable, disease-modifying outcomes rather than chronic symptom management.

Our second platform includes the Ariadne-Fly and Dragon-Fly series, which are designed to target neurodegenerative disorders. We believe these compounds have the potential to be highly efficacious in conditions such as Parkinson’s disease and dementia, where current therapeutic options remain limited and largely palliative.

As a team of motivated chemists and pharmacologists, we are uniquely positioned to translate these compounds from discovery through development. We are actively seeking investors who are willing to partner with us and give us the opportunity to demonstrate what our science—and our team—are capable of delivering.